EGF-R expression in ductal breast cancer: Proliferation and prognostic implications

Barbara Bucci, Igea D'Agnano, Claudio Botti, Marcella Mottolese, Elisabetta Carico, Gabriella Zupi, Aldo Vecchione

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We studied epidermal growth factor receptor (EGF-R) expression in relation to steroid receptor status, flow cytometric DNA content and S-phase fraction (%S) in a selected case series of 129 ductal primary operable breast cancer to determine the possible role of EGF-R in prognosis assessment. EGF-R expression was positively related with proliferation activity suggesting that EGF-R could be involved in the regulation of breast cancer cell growth. We found about 80% of highly proliferating DNA aneuploid tumors in the EGF-R positive category, while the EGF-R negative tumors showed a lower frequency of highly proliferating DNA aneuploid tumors (57%), confirming the important role of EGF-R in breast cancer aggressiveness and progression. No relationship between EGF-R expression and steroid receptor status was observed. To better understand how EGF-R and estrogen receptor (ER) operate together to stimulate breast cancer cell growth, we analyzed the %S in the two groups of ER negative (ER-) and ER positive (ER+) tumors, stratifying the patients on the basis of EGF-R tumor positivity. Here breast tumor proliferation activity seems mainly to be induced by the stimulus of EGF-R, the %S values of the EGF-R negative tumors in the ER- and ER+ groups being 6.1 and 6.9%, respectively. Instead, the median %S of EGF-R positive tumors was 10% in the ER- class and 14% in the ER+ group. The analysis of the percentages of 5-year patient disease free survival were 84% for patients with EGF-R negative tumors and 61% for patients with EGF-R positive lesions, respectively. The data reported here further show the crucial role of EGF-R in breast cancer cell growth and that the EGF-R overexpression is indicative of a poor prognosis.

Original languageEnglish
Pages (from-to)769-774
Number of pages6
JournalAnticancer Research
Volume17
Issue number1 B
Publication statusPublished - 1997

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Estrogen Receptors
Neoplasms
Steroid Receptors
Aneuploidy
DNA
Growth
S Phase
Disease-Free Survival

Keywords

  • %S
  • Breast cancer
  • DNA content
  • EGF-R
  • Flow cytometry
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bucci, B., D'Agnano, I., Botti, C., Mottolese, M., Carico, E., Zupi, G., & Vecchione, A. (1997). EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Research, 17(1 B), 769-774.

EGF-R expression in ductal breast cancer : Proliferation and prognostic implications. / Bucci, Barbara; D'Agnano, Igea; Botti, Claudio; Mottolese, Marcella; Carico, Elisabetta; Zupi, Gabriella; Vecchione, Aldo.

In: Anticancer Research, Vol. 17, No. 1 B, 1997, p. 769-774.

Research output: Contribution to journalArticle

Bucci, B, D'Agnano, I, Botti, C, Mottolese, M, Carico, E, Zupi, G & Vecchione, A 1997, 'EGF-R expression in ductal breast cancer: Proliferation and prognostic implications', Anticancer Research, vol. 17, no. 1 B, pp. 769-774.
Bucci B, D'Agnano I, Botti C, Mottolese M, Carico E, Zupi G et al. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Research. 1997;17(1 B):769-774.
Bucci, Barbara ; D'Agnano, Igea ; Botti, Claudio ; Mottolese, Marcella ; Carico, Elisabetta ; Zupi, Gabriella ; Vecchione, Aldo. / EGF-R expression in ductal breast cancer : Proliferation and prognostic implications. In: Anticancer Research. 1997 ; Vol. 17, No. 1 B. pp. 769-774.
@article{0b8bcb9b4f7843c987418397abe2d091,
title = "EGF-R expression in ductal breast cancer: Proliferation and prognostic implications",
abstract = "We studied epidermal growth factor receptor (EGF-R) expression in relation to steroid receptor status, flow cytometric DNA content and S-phase fraction ({\%}S) in a selected case series of 129 ductal primary operable breast cancer to determine the possible role of EGF-R in prognosis assessment. EGF-R expression was positively related with proliferation activity suggesting that EGF-R could be involved in the regulation of breast cancer cell growth. We found about 80{\%} of highly proliferating DNA aneuploid tumors in the EGF-R positive category, while the EGF-R negative tumors showed a lower frequency of highly proliferating DNA aneuploid tumors (57{\%}), confirming the important role of EGF-R in breast cancer aggressiveness and progression. No relationship between EGF-R expression and steroid receptor status was observed. To better understand how EGF-R and estrogen receptor (ER) operate together to stimulate breast cancer cell growth, we analyzed the {\%}S in the two groups of ER negative (ER-) and ER positive (ER+) tumors, stratifying the patients on the basis of EGF-R tumor positivity. Here breast tumor proliferation activity seems mainly to be induced by the stimulus of EGF-R, the {\%}S values of the EGF-R negative tumors in the ER- and ER+ groups being 6.1 and 6.9{\%}, respectively. Instead, the median {\%}S of EGF-R positive tumors was 10{\%} in the ER- class and 14{\%} in the ER+ group. The analysis of the percentages of 5-year patient disease free survival were 84{\%} for patients with EGF-R negative tumors and 61{\%} for patients with EGF-R positive lesions, respectively. The data reported here further show the crucial role of EGF-R in breast cancer cell growth and that the EGF-R overexpression is indicative of a poor prognosis.",
keywords = "{\%}S, Breast cancer, DNA content, EGF-R, Flow cytometry, Prognostic factors",
author = "Barbara Bucci and Igea D'Agnano and Claudio Botti and Marcella Mottolese and Elisabetta Carico and Gabriella Zupi and Aldo Vecchione",
year = "1997",
language = "English",
volume = "17",
pages = "769--774",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - EGF-R expression in ductal breast cancer

T2 - Proliferation and prognostic implications

AU - Bucci, Barbara

AU - D'Agnano, Igea

AU - Botti, Claudio

AU - Mottolese, Marcella

AU - Carico, Elisabetta

AU - Zupi, Gabriella

AU - Vecchione, Aldo

PY - 1997

Y1 - 1997

N2 - We studied epidermal growth factor receptor (EGF-R) expression in relation to steroid receptor status, flow cytometric DNA content and S-phase fraction (%S) in a selected case series of 129 ductal primary operable breast cancer to determine the possible role of EGF-R in prognosis assessment. EGF-R expression was positively related with proliferation activity suggesting that EGF-R could be involved in the regulation of breast cancer cell growth. We found about 80% of highly proliferating DNA aneuploid tumors in the EGF-R positive category, while the EGF-R negative tumors showed a lower frequency of highly proliferating DNA aneuploid tumors (57%), confirming the important role of EGF-R in breast cancer aggressiveness and progression. No relationship between EGF-R expression and steroid receptor status was observed. To better understand how EGF-R and estrogen receptor (ER) operate together to stimulate breast cancer cell growth, we analyzed the %S in the two groups of ER negative (ER-) and ER positive (ER+) tumors, stratifying the patients on the basis of EGF-R tumor positivity. Here breast tumor proliferation activity seems mainly to be induced by the stimulus of EGF-R, the %S values of the EGF-R negative tumors in the ER- and ER+ groups being 6.1 and 6.9%, respectively. Instead, the median %S of EGF-R positive tumors was 10% in the ER- class and 14% in the ER+ group. The analysis of the percentages of 5-year patient disease free survival were 84% for patients with EGF-R negative tumors and 61% for patients with EGF-R positive lesions, respectively. The data reported here further show the crucial role of EGF-R in breast cancer cell growth and that the EGF-R overexpression is indicative of a poor prognosis.

AB - We studied epidermal growth factor receptor (EGF-R) expression in relation to steroid receptor status, flow cytometric DNA content and S-phase fraction (%S) in a selected case series of 129 ductal primary operable breast cancer to determine the possible role of EGF-R in prognosis assessment. EGF-R expression was positively related with proliferation activity suggesting that EGF-R could be involved in the regulation of breast cancer cell growth. We found about 80% of highly proliferating DNA aneuploid tumors in the EGF-R positive category, while the EGF-R negative tumors showed a lower frequency of highly proliferating DNA aneuploid tumors (57%), confirming the important role of EGF-R in breast cancer aggressiveness and progression. No relationship between EGF-R expression and steroid receptor status was observed. To better understand how EGF-R and estrogen receptor (ER) operate together to stimulate breast cancer cell growth, we analyzed the %S in the two groups of ER negative (ER-) and ER positive (ER+) tumors, stratifying the patients on the basis of EGF-R tumor positivity. Here breast tumor proliferation activity seems mainly to be induced by the stimulus of EGF-R, the %S values of the EGF-R negative tumors in the ER- and ER+ groups being 6.1 and 6.9%, respectively. Instead, the median %S of EGF-R positive tumors was 10% in the ER- class and 14% in the ER+ group. The analysis of the percentages of 5-year patient disease free survival were 84% for patients with EGF-R negative tumors and 61% for patients with EGF-R positive lesions, respectively. The data reported here further show the crucial role of EGF-R in breast cancer cell growth and that the EGF-R overexpression is indicative of a poor prognosis.

KW - %S

KW - Breast cancer

KW - DNA content

KW - EGF-R

KW - Flow cytometry

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0031048942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031048942&partnerID=8YFLogxK

M3 - Article

C2 - 9066618

AN - SCOPUS:0031048942

VL - 17

SP - 769

EP - 774

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -